Skip to main content
. 2025 Feb 4;36(5):383–393. doi: 10.1097/CAD.0000000000001697

Table 3.

Response of patients with measurable disease

All (n = 71) Group A (n = 43) Group B (n = 28)
PR 12 (17%) 6 (14%) 6 (21%)
SD 52 (73%) 31 (72%) 21 (75%)
PD 4 (6%) 3 (7%) 1 (4%)
Unknown 3 (4%) 3 (7%) 0 (0%)
ORR 17% 14% 21%
P value (ORR) 0.494
χ 2 0.468
DCR 90% 86% 96%
P value (DCR) 0.498
χ 2 0.459

Group A, CAPEOX + Cetuximab; Group B, FOLFOX + Cetuximab.

DCR, disease control rate; ORR, objective response rate; PD, progression disease; PR, partial response; SD, stable disease.